Document is current
Any future updates will be listed below
-
Authors
Tanner, Mark R.
Pennington, Michael W.
Chauhan, Satendra S.
Laragione, Teresina
Gulko, Pércio S.
Beeton, Christine https://orcid.org/0000-0002-2500-5874
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS073712)
Arthritis Foundation (6483)
National Institute of General Medical Sciences (GM088129)
National Institute of Allergy and Infectious Diseases (AI053831)
National Heart, Lung, and Blood Institute (HL007676)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR069960)
National Institutes of Health (HG006348, RR024574)
National Cancer Institute (CA125123)
- License Information
-
More Information
Article History
Received: 3 September 2018
Accepted: 29 November 2018
First Online: 7 January 2019
Ethics approval
: The experiments involving the use of rats were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine. De-identified human FLS were isolated by PSG’s group after patients provided written consent for their tissues to be studied, as approved by the Institutional Review Board at the Feinstein Institute for Medical Research. Baylor College of Medicine’s Institutional Review Board determined that the study of these cells did not constitute human research, because the samples were de-identified.
: Not applicable.
: CB and MWP are inventors on the patent for ShK-186/dalazatide. CB and MWP are cofounders of Airmid, Inc., and sit on its board of directors. CB and MWP are investors in Kineta, Inc. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
